Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer
Details
Publication Year 2023-05-08,Volume 41,Issue #5,Page 821-823
Journal Title
Cancer Cell
Publication Type
Correspondence
Abstract
Wu et al. report that patients with hematologic malignancies have reduced immunity against SARS-CoV-2 Omicron subvariants and Sotrovimab retains neutralizing capacity against all tested Omicron subvariants.
Publisher
Cell Press
Keywords
Humans; *covid-19; SARS-CoV-2; *Hematologic Neoplasms/drug therapy; *Neoplasms
Department(s)
Medical Oncology
PubMed ID
37116490
Open Access at Publisher's Site
https://doi.org/10.1016/j.ccell.2023.04.005
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2023-09-05 06:33:38
Last Modified: 2023-09-05 06:34:32

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙